Member Info for Soupdragon78

Scratch that… 2 days left this week. Forgot it’s only Wednesday.

Not a bad day all round, as we end the week we know more about the strategy moving forwards than we have done for a long time.

Just one more day left this week....

Have to admit the MM's playing a blinder at the moment, basically anyone who bought this morning after 08.02am can only sell at a loss.

Going to be the test now, punters who bought this morning now facing the choice of whether to hold or not. Someone just sold their 421k three hours after buying it at 0.47

Indeed chab, lots refusing to move the bid up, which means some traders have been rinsed already this morning.

Doesn’t help when the PR company hired by Riddell are so incompetent they can’t even get the right product on their announcement tweet.

As long as any prospective chairman moves the sp in the opposite direction to where AR was taking it then I don’t mind.

It’s almost like they can operate without a chairman ;-)

FX, they haven’t spoke to anyone commercially, the previous announcements always said it would be after patent is granted.

Now going toe to toe with Lynparza!

Dr G is a dab hand at these RNS’s

Thanks for your concern mulder.
I make my choices, you make yours... its that simple.

You chose to post under multiple usernames and got found out... that was your choice.

Do you indeed...

Alex is still employed, he and JH do all the formulation work.

1 staff and 2 consultants.

Don't forget little Alex who's doing the work.

CEO I can see the point of, but Chairman is mostly old hat and for large boards. Most companies don’t benefit from having one.

They've finally removed AR from the website now.

FX, you're concerns over Nuformix Tech should now be eased. Gilbert and Maddy are now directors.

"The Company has now initiated further studies as it continues to generate a robust pre-clinical data package to support the progression of NXP002, both in terms of product development and business development discussions."

As I've been mentioning before, this all stacks up to keep the ball rolling through H2 of this year.

NXP001 - Due to be in phase 1 clinical trials this year with milestone payments to NFX
NXP002 - Development milestones due post-August through H2.
NXP004 - Being developed as preclinical now.

One to note indirectly, Monument Therapeutics collaboration with TRx Bioscience is now underway in Phase 1 trials. Julian Gilbert is NED at Monument and TRx are involved with Oxilio on NXP001, so shows these companies aren't standing still.

I get that jiving, but for me it’s good that they get the product back on track as the priority, then they have time to properly organise the company structure.